DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for follicular lymphoma — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFollicular lymphoma maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for follicular lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Bruton tyrosine kinase (BTK) — BTK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 7h-pyrrolo[2,3-d]pyrimidin-4-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VXQ · 1.4 Å · ligand N-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl}benzamide (RQS). Experimental structure, not a prediction.
What the evidence adds up to
For early stage follicular lymphoma, radiation therapy has been the predominant treatment for decades, producing a 10-year progression-free survival of 45–60% and thought to represent cures in a disease otherwise considered incurable with conventional modalities. Limiting the radiation field and dose does not diminish outcomes, and adding chemotherapy does not benefit this patient population as a whole. Despite these results, a minority of patients in the United States receive radiation; the majority are instead observed or treated with chemoimmunotherapy. For patients in whom radiation would be too toxic or who prefer not to have it, observation is a reasonable alternative, and a proportion of observed patients do not require therapy for a number of years.
The choice of treatment for follicular lymphoma is highly dependent on patient and disease characteristics. For limited disease, options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. For advanced disease, treatment is often determined by tumour burden: surveillance or rituximab for low tumour burden, and chemoimmunotherapy for high tumour burden disease. For relapsed or refractory disease, treatment is influenced by initial first-line therapy and the duration and quality of the response. At present, there is no consensus for treatment of patients with early or multiply-relapsed disease, though numerous agents, combination regimens, and transplant options have demonstrated efficacy.
Several tools are available for risk stratification, but limitations in their routine clinical use exist. The use of polymerase chain reaction for Bcl-2 gene rearrangements to detect molecular disease may identify patients with early occult disseminated disease who are at risk for relapse and would benefit from the addition of systemic therapy. Prognosis for early and advanced stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The modern management of follicular lymphoma should consist of personalisation of therapy related to risk factors.
What is still missing is a consensus on the best approach to select the most appropriate treatment strategy for an individual patient at a particular time. The number of therapies available has increased, but the optimal sequencing and combination of these agents, and the identification of which patients will benefit from which strategy, remain unresolved. Limitations in the routine clinical use of existing risk stratification tools, and the lack of a standard approach for early or multiply-relapsed disease, are ongoing gaps.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Journal Of Haematology · 2019 · 56 citations · open access
Diagnosis and management of follicular lymphoma: A comprehensive review
AbstractFollicular Lymphoma (FL) is an indolent lymphoma and may have various clinical courses. Worldwide, FL is the second most common non-Hodgkin lymphoma (NHL) type after diffuse large B-cell lymphoma. In this review article, the author is discussing relevant diagnostic tools, prognostic factors, and updated study results on the management of patients with newly diagnosed and relapsed/refractory FL. Controversies in the treatment, maintenance therapy, stem cell transplantation, and novel treatment approaches will be comprehensively discussed.
Early stage follicular lymphoma, current management and controversies
AbstractPURPOSE OF REVIEW: In this article, we focus on the epidemiology, outcomes, and treatment options of early stage follicular lymphoma. RECENT FINDINGS: Radiation therapy has been the predominant treatment for patients with early stage follicular lymphoma for decades. It is associated with a 10-year progression-free survival of 45-60%, thought to represent cures in this otherwise incurable disease with conventional modalities. Limiting the radiation field and dose does not diminish outcomes. On the contrary, the addition of chemotherapy does not benefit this patient population as a whole. The use of polymerase chain reaction for Bcl-2 gene rearrangements to detect molecular disease, however, may identify patients with early occult disseminated disease, who are at risk for relapse and would benefit from the addition of systemic therapy. For patients in whom radiation would be too toxic or prefer to not have radiation, observation is a reasonable alternative and a proportion of patients observed do not require therapy for a number of years. Despite the potential cures achieved by radiation therapy, a minority of patients in the United States receive such therapy; the majority are instead observed or treated with chemoimmunotherapy. SUMMARY: Patients with early stage follicular lymphoma enjoy excellent outcomes following definitive radiation therapy, many of whom may even be cured. The addition of other therapies has not enhanced cure rates but identifying patients at greatest risk for disease relapse may change this paradigm. Despite the proven success of radiation, the majority of early stage follicular lymphoma patients in the United States do not receive radiation.
The Cancer Journal · 2020 · 11 citations · open access
Advances in Treatment of Follicular Lymphoma
AbstractFollicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early and advanced stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. At present, there is no consensus for treatment of patients with early or multiply-relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. While the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This chapter considers prognostic factors and the evolving treatment landscape of FL, including recent and emerging therapies, as well as remaining unmet needs.
AbstractFollicular lymphoma is one of the most common neoplastic lymphoproliferative diseases encountered in the western world. Intensive scientific scrutiny has led to detailed understanding of the nature of the malignant cell and the specific genetic abnormalities which are frequently encountered and likely to be etiologic. Clinical research focusing on the treatment of follicular lymphoma continues to reveal new insights into the natural history of the disease. Investigations reported during the past year have focused on a number of important issues with regard to the management of patients with the diseases.
Personalizacja leczenia chorych na chłoniaka grudkowego w dobie rutyksymabu
AbstractIn patients with follicular lymphoma (FL), there are several factors influencing the disease course: morphological, immunological, genetic and clinical. The therapeutic options for patients with FL contain many methods such as rituximab with different chemotherapy regimens, radioimmunotherapy, radiotherapy and hematopoietic stem cell transplantation. The modern management of FL patients should consist of personalization of therapy related to risk factors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
